Literature DB >> 15661053

Construction of the Mandarin version of the International Prostate Symptom Score inventory in assessing lower urinary tract symptoms in a Malaysian population.

Kia Fatt Quek1, Chong Beng Chua, Azad Hassan Razack, Wah Yun Low, Chit Sin Loh.   

Abstract

BACKGROUND: The purpose of the present study was to validate the Mandarin version of the International Prostate Symptom Score (Mand-IPSS) in a Malaysian population.
METHODS: The validity and reliability were studied in patients with lower urinary tract symptoms (LUTS; benign prostatic hyperplasia [BPH] group) and without LUTS (control group). Test-retest methodology was used to assess the reliability while Cronbach alpha was used to assess the internal consistency. Sensitivity to change was used to express the effect size index in the preintervention versus post-intervention score in patients with LUTS who underwent transurethral resection of the prostate.
RESULTS: For the control group and BPH group, the internal consistency was excellent and a high degree of internal consistency was observed for all seven items (Cronbach alpha = 0.86-0.98 and 0.90-0.98, respectively). Test-retest correlation coefficients for all items were highly significant. Intraclass correlation coefficient (ICC) was high for the control (ICC = 0.93-0.99) and BPH group (ICC = 0.91-0.99). The sensitivity and specificity showed a high degree of sensitivity and specificity to the effects of treatment. A high degree of significance between baseline and post-treatment scores was observed across all seven items in the BPH group but not in the control group.
CONCLUSIONS: The Mand-IPSS is a suitable, reliable, valid and sensitive instrument to measure clinical change in the Malaysian population.

Entities:  

Mesh:

Year:  2005        PMID: 15661053     DOI: 10.1111/j.1442-2042.2004.00988.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  7 in total

1.  Frequency and Pattern of Lower Urinary Tract Symptoms in a screened population of Men above 40 Years in Ibadan, Southwestern Nigeria.

Authors:  E O Olapade-Olaopa; E T Owoaje; M M Ladipo; O A Fadimu; O Muoka; T G Adedeji
Journal:  J West Afr Coll Surg       Date:  2015 Oct-Dec

2.  Prostatic capsule- and nerve-sparing cystectomy in organ-confined bladder cancer: preliminary results.

Authors:  Gianni Martis; Gianluca D'Elia; Massimo Diana; Maurizio Ombres; Bruno Mastrangeli
Journal:  World J Surg       Date:  2005-10       Impact factor: 3.352

3.  The Modified Urdu version of International Prostate Symptom Score: A psychometric validation study.

Authors:  Muhammad Salman; Amer Hayat Khan; Syed Azhar Syed Sulaiman; Jeffery Hughes; Junaid Habib Khan; Khalid Hussain
Journal:  Turk J Urol       Date:  2018-07

4.  Cross-cultural adaptation and validation of the Serbian version of the ICS SF male questionnaire.

Authors:  Uros Babic; Milena Santric-Milicevic; Vesna Bjegovic-Mikanovic; Aleksandar Argirovic; Mihailo Stjepanovic; Dejan Lazovic; Djordje Nale; Milan Perovic; Stefan Dugalic; Vinka Vukotic
Journal:  ScientificWorldJournal       Date:  2015-02-15

5.  Validation of the International Prostate Symptom Score in Chinese males and females with lower urinary tract symptoms.

Authors:  Edmond P H Choi; Cindy L K Lam; Weng-Yee Chin
Journal:  Health Qual Life Outcomes       Date:  2014-01-02       Impact factor: 3.186

6.  Simplified Chinese version of the international prostate symptom score and the benign prostatic hyperplasia impact index: cross-cultural adaptation, reliability, and validity for patients with benign prostatic hyperplasia.

Authors:  Rong-Liang Dun; Jian-Min Mao; Chao Yu; Qiang Zhang; Xiao-Hua Hu; Wen-Jing Zhu; Guang-Chong Qi; Yu Peng
Journal:  Prostate Int       Date:  2022-05-10

7.  Misinterpretation of the international prostate symptom score questionnaire by Indian patients.

Authors:  Tarun Jindal; Rajan Kumar Sinha; Subhabrata Mukherjee; Soumendra Nath Mandal; Dilip Karmakar
Journal:  Indian J Urol       Date:  2014-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.